← Companies
Sponsor / Institution
Assistance Publique - Hopitaux de Paris
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs
2
linked to organization
Strong Evidence
0
0 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
0 / 2
industry vs non-industry records
Competitive Density
6
Pipeline Velocity
100
Completion Signal
100
Programs by Stage
Phase 32
Trial / Program Status
Active2
Modality Mix
Small Molecule2
Indication Coverage
Hearing Loss2
Sensorineural Hearing Loss2
Congenital CMV-Associated Hearing Loss1
Sudden Hearing Loss1
Program Types
Therapeutic2
Population Tags
sensorineural2
adult1
cmv1
congenital1
infant1
pediatric1
ssnhl1
sudden1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksValganciclovir for congenital CMV-associated hearing loss
Details checked
Small MoleculePhase 3Active
Oral valganciclovir, a ganciclovir prodrug antiviral, evaluated to suppress congenital cytomegalovirus replication and reduce or stabilize CMV-associated sensorineural hearing-loss progression in infants and young children.
Data checks: generic-drug-study-cluster, not-industry-sponsored-pipeline-program
AP-HP SERORL aspirin and folic acid SSNHL study
Details checked
Small MoleculePhase 3Active
Adjunctive aspirin 100 mg/day plus folic acid 5 mg/day, added to standard corticosteroid care, being evaluated for sudden sensorineural hearing loss based on a microvascular/homocysteine hypothesis.
Data checks: institution-led-study, not-yet-recruiting